Summary of Praxis Precision Medicines FY Conference Call Company Overview - **Company**: Praxis Precision Medicines (NasdaqGS:PRAX) - **Key Products**: ULYXIA (for essential tremor), relutrigine (for epilepsy) Core Industry Insights - **Market Size**: The addressable market for essential tremor is over 2 million patients at peak, significantly larger than previously anticipated [15][16] - **Regulatory Strategy**: The company opted for a standard review process for ULYXIA instead of a priority review to maintain a strong relationship with the FDA and maximize revenue potential before IRA negotiations begin [15][16] Key Points Discussed 1. **NDA Submission**: The NDA for ULYXIA has been submitted, and the company is not requesting priority review, anticipating a standard review process [7][15] 2. **FDA Relationship**: The company has maintained continuity in its interactions with the FDA, with no significant staff changes in the review team since the end of Phase 2 meetings [19][20] 3. **Titration Schedule**: The NDA submission included a standard titration schedule, with a proposal to allow clinicians to maintain a 20-milligram dose for an extra week if tolerability issues arise [30][34] 4. **Patient Tolerability**: Approximately 30% of patients may experience dizziness, which could lead to discontinuation of the drug; however, the company believes that maintaining the 20-milligram dose could resolve this issue for most patients [32][34] 5. **Pre-Launch Activities**: The company is focusing on disease awareness and prescriber identification to prepare for the ULYXIA launch, targeting over 200,000 patients interested in clinical trials [58][71] 6. **Sales Force Strategy**: The company plans to hire around 300 sales representatives to ensure adequate coverage and demand generation for ULYXIA, rather than starting with a smaller team and scaling up [126][127] 7. **Pricing Strategy**: The pricing for ULYXIA is expected to reflect its innovative nature, with a potential starting point in the mid-range of existing treatments for similar conditions [112][114] 8. **Relutrigine Development**: The company is also preparing for the launch of relutrigine, which is expected to receive priority review, with a PDUFA date likely in Q4 [135] Additional Important Insights - **Market Dynamics**: The company anticipates a large volume of patients seeking treatment for essential tremor, with about 1 million patients seen by neurologists annually for prescriptions [76][77] - **Community Engagement**: The company is focusing on building relationships with both specialized centers and community neurologists to ensure effective patient referrals and education [140][141] - **Future Data Catalysts**: Upcoming data from the POWER1 study for vormatrigine is expected to show significant efficacy, with a target of 30% placebo-adjusted seizure reduction [152][154] - **Ongoing Studies**: The phase 3 study for Elsunersen is progressing well, with an amendment to remove sham controls based on FDA recommendations [160][162] This summary encapsulates the key discussions and strategic insights from the Praxis Precision Medicines FY Conference Call, highlighting the company's focus on regulatory strategy, market preparation, and product development.